Transaction DateRecipientSharesTypePriceValue
28th December 2020Mark G Currie20,107Open or private sale$3.01$60,522.07
8th December 2020Terrance Mcguire51,457Conversion of derivative$0.00
8th December 2020Terrance Mcguire78,947Open or private purchase$19.00$1,499,993.00
9th November 2020Andreas Busch125,000Open or private purchase$2.53$316,250.00
23rd June 2020Terrance Mcguire4,377Open or private sale$31.54$138,062.84
23rd June 2020Marsha Fanucci33,781Open or private sale$0.00
23rd June 2020Marsha Fanucci14,026Open or private sale$0.00
23rd June 2020Marsha Fanucci10,240Open or private sale$0.00
23rd June 2020Marsha Fanucci9,847Open or private sale$0.00
23rd June 2020Marsha Fanucci52,532Open or private purchase$0.00
Cyclerion Therapeutics
Cyclerion Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 4/10.


Cyclerion Therapeutics, Inc. engages in the discovery, development, and commercialization of treatments for serious and orphan diseases. Its product pipeline includes several sGC stimulators. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.


Ticker: CYCN
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1755237
Employees: 94
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals